Author

Manu M. Sebastian

The University of Texas MD Anderson Cancer CenterORCID 0000-0002-9229-8750Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Organism:human· 1 Assay:imaging· 1 Research Focus:perturbation response prediction· 1 Assay:proteomics· 1

Frequent Co-Authors

Daric J. WibleiD· 1 shared David Piwnica-Worms· 1 shared Dean G. TangiD· 1 shared Federica PisaneschiiD· 1 shared Hira MazhariD· 1 shared Margie Nicole SuttoniD· 1 shared Nicholas BlazaniniD· 1 shared Phuong Kieu Nguyen· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Daric J. WibleORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Anti-Cancer Immune Priming with Beta-Radioligand Therapy and Isoform-Selective Targeting of 4Ig-B7-H3

Sarah E. Glazer, Margie Nicole Sutton, Ping Yang, Federica Pisaneschi, Manu M. Sebastian, Seth T. Gammon, David Piwnica-Worms

This paper develops a monoclonal antibody targeting 4Ig-B7-H3 for beta-radioligand therapy, showing improved tumor-specific binding and immune priming effects in preclinical models.

Theranostics · Mar 12, 2026Peer-reviewedCancer Biology

Loss of ATG5 expression in a subset of human prostate cancers promotes tumor growth through accumulation of p62

Daric J. Wible, Wen Jess Li, Xiaozhuo Liu, Manu M. Sebastian, Dean G. Tang, Shawn B. Bratton

The paper shows that loss of ATG5 in prostate cancers leads to tumor growth by accumulating p62, suggesting ATG5 acts as a tumor suppressor in this context.

bioRxiv · May 2, 2025 · PreprintCancer Biology

Discovery of Novel, Potent and Orally Bioavailable SMARCA2 PROTACs with Synergistic Anti-tumor Activity in Combination with KRAS G12C Inhibitors.

Sasikumar Kotagiri, Yawen Wang, Yanyan Han, Xiaobing Liang, Nicholas Blazanin, Hira Mazhar, Manu M. Sebastian, Phuong Kieu Nguyen, Yongying Jiang, Yonathan Lissanu

This paper discovers and characterizes potent SMARCA2 PROTACs that show anti-tumor activity and synergize with KRAS G12C inhibitors in SMARCA4 mutant lung cancer.

Journal of Medicinal Chemistry · Apr 25, 2025Peer-reviewedCancer Biology